- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03818438
Chronic Ankle Instability Diagnostic Tests Determining Underlying Deficits (CAIDiag)
Biomechanical Analysis, Complementary Examinations and Rehabilitative Management of Chronic Ankle Instability
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Saint-Omer, France
- CH Saint-Omer, institut audomarois de la chirurgie orthopédique et du sport
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Case subject : at least one initial lateral ankle sprain more than 12 months before inclusion
- Case subject : at least one residual symptom among (1) giving way, (2) sensation of instability, (3) recurrent ankle sprain. This item is confirmed by a score inferior than 24 on the Chronic Ankle Instability Tool (CAIT)
- Case subject : Impact on activities of daily living and sport, confirmed by a score of less than 90% on the Foot and Ankle Ability Measure (FAAM) and less than 80% on FAAM-- - -- Control subject : matched by age and sex to case subjects
Exclusion Criteria:
- Surgery of one of the lower limbs less than 3 years ago
- Presence of heavy pain (EVA > 8) regardless of its origin
- Acute lateral ankle sprain less than 4 months before inclusion
- Neurological disorders of any kind
- Medical treatment (drugs) interfering with muscle tone, balance and proprioception disorders
- Pregnant or breastfeeding women
- Body mass index > 30
- Bilateral chronic ankle instability
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Case subjects adult patients with chronic ankle instability
Male or female subjects aged 18-45, presenting :
|
|
Healthy subjects
Male or female subjects aged 18-45 (matched with case Healthy subjects), without any lower extremity pathologies
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Static balance tests
Time Frame: Baseline
|
Static balance tests ( DLS and SLS (both ankles tested) ; Stabilometry) are composite measure
|
Baseline
|
|
the Star Excursion Balance Test (SEBT)
Time Frame: Baseline
|
Dynamic balance test : SEBT (both ankles tested) : are composite measure
|
Baseline
|
|
Hop tests
Time Frame: Baseline
|
Hop tests (both ankles tested) : SLHD et SH ; are composite measure
|
Baseline
|
|
Strength tests (both ankles tested)
Time Frame: Baseline
|
Isokinetic strength tests (both ankles tested) :
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intra-class correlation coefficients (reproducibility test-retest)
Time Frame: Baseline and 1-4 weeks after baseline
|
Intra-class correlation coefficients (reproducibility test-retest) calculated on the subset of the parameters identified by the main analysis. Recyclability of the functional clinical tests : Normality testing /Sample comparison |
Baseline and 1-4 weeks after baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Alexandre Arnould, MD, University Hospital, Lille
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017_09
- 2018-A00102-53 (Other Identifier: ID-RCB number, ANSM)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.